23:58 , Nov 28, 2018 |  BC Extra  |  Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
22:04 , Aug 14, 2018 |  BC Extra  |  Company News

Management tracks: Cheng departing Gilead as CMO

Gilead Sciences Inc. (NASDAQ:GILD) said CMO Andrew Cheng will leave the company, effective Sept. 7, after five months in the role to pursue another opportunity. Gilead did not say who would replace Cheng, who joined...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , Apr 21, 2016 |  BC Innovations  |  Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

A1M Pharma, NeuroVive deal

A1M and NeuroVive partnered to conduct research in mitochondrial medicine. The companies will initially utilize their "complementary scientific platforms" in ongoing research projects, after which they will explore the possibility of a "closer collaboration." Each...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

PRO051: Additional Extension study data

Additional data from an extension phase of a 5-week, open-label Phase I/IIa trial in 12 patients ages 5-16 showed that weekly subcutaneous PRO051 improved mean 6-minute walking distance (6MWD) by 35.2 meters from baseline at...